GLP-1 receptor agonists were initially developed to improve glycemic control in type 2 diabetes by enhancing insulin secretion and inhibiting glucagon release, with additional effects on appetite regulation and gastric emptying later recognized as clinically relevant (Chao et al
Saroka RM, Kane MP, Busch RS, Watsky J, Hamilton RA
In clinical practice it has been largely superseded by once-weekly semaglutide, though it remains a licensed option
Insurance and Coverage Considerations Canadian private insurance plans increasingly cover GLP-1 based weight loss medications, though coverage varies widely
This list isn't exhaustive - your assigned clinician will review your full health history and current medications before making any prescribing determination
Others want fat loss with muscle preservation